Axxam Overview
- Year Founded
-
2001
- Status
-
Private
- Employees
-
200
- Latest Deal Type
-
Buyout/LBO
- Financing Rounds
-
1
- Investments
-
5
Axxam General Information
Description
Provider of drug discovery services intended for the life sciences industry. The company offers target assessment, assay development, high-throughput screening, hit qualification, and hit-to-lead generation, designed to support pharmaceutical and biotechnology firms in translating innovative biology into bioactive molecules.
Contact Information
Website
www.axxam.comCorporate Office
- Openzone Campus, Via Meucci, 3
- Bresso
- 20091 Milan
- Italy
Corporate Office
- Openzone Campus, Via Meucci, 3
- Bresso
- 20091 Milan
- Italy
Axxam Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Axxam Patents
Axxam Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2023031319-A1 | 2,4-dihydro-3h-1,2,4-triazol-3-one p2x7 antagonists | Inactive | 03-Sep-2021 | ||
| EP-4015039-A1 | Heterocyclic derivatives as p2x7 receptor antagonists | Inactive | 18-Dec-2020 | ||
| WO-2022129365-A1 | Heterocyclic derivatives as p2x7 receptor antagonists | Inactive | 18-Dec-2020 | ||
| AU-2020316080-A1 | Bicyclic cx3cr1 receptor agonists | Inactive | 23-Jul-2019 | ||
| CA-3148454-A1 | Bicyclic cx3cr1 receptor agonists | Pending | 23-Jul-2019 | C07D409/12 |
Axxam Signals
Axxam Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Axxam Investments & Acquisitions (5)
Axxam’s most recent deal was a Early Stage VC with Lario Therapeutics for . The deal was made on 07-Nov-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Lario Therapeutics | 07-Nov-2023 | Early Stage VC | Drug Discovery | ||
| Hit Discovery Constance | 12-Jan-2022 | Merger/Acquisition | Other Pharmaceuticals and Biotechnology | ||
| Rewind Therapeutics | 04-Jan-2018 | Early Stage VC | Drug Discovery | ||
| Acousia Therapeutics | 14-Dec-2016 | Early Stage VC | Drug Discovery | ||
| Hit Discovery Constance | 01-Jan-2013 | Joint Venture | Other Pharmaceuticals and Biotechnology |
Axxam Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Hit Discovery Constance | Konstanz, Germany | 2013 |
Axxam FAQs
-
When was Axxam founded?
Axxam was founded in 2001.
-
Where is Axxam headquartered?
Axxam is headquartered in Milan, Italy.
-
What is the size of Axxam?
Axxam has 200 total employees.
-
What industry is Axxam in?
Axxam’s primary industry is Drug Discovery.
-
Is Axxam a private or public company?
Axxam is a Private company.
-
What is Axxam’s current revenue?
The current revenue for Axxam is .
-
Who are Axxam’s investors?
Keensight Capital has invested in Axxam.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process